Drugs / NBP2001
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04760743 | Dec 2020 → Apr 2021 | — | SK Bioscience Co., Ltd. | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2020-12-10 | SK Bioscience Co., Ltd. | Regulatory SK bioscience’s COVID-19 Vaccine Candidate Is Chosen to First ‘Wave2’ Supporting Candidate skbioscience.com ↗
SK bioscience received the approval from the KMFDS on the 23rd of last month for its investigational new drug of ‘NBP2001,’ another COVID-19 vaccine candidate. |
| 2020-11-25 | SK Bioscience Co., Ltd. | Regulatory SK bioscience’s COVID-19 Vaccine Candidate Enters Clinical Trial skbioscience.com ↗
SK bioscience announced on the 24th that the company’s COVID-19 vaccine candidate ‘NBP2001’ has obtained a final approval from the Ministry of Food and Drug Safety(KMFDS) for an Investigational New Drug(IND) Phase I clinical trial. |
All press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2020-12-10 | SK Bioscience Co., Ltd. | SK bioscience’s COVID-19 Vaccine Candidate Is Chosen to First ‘Wave2’ Supporting Candidate skbioscience.com ↗ |
| 2020-12-02 | SK Bioscience Co., Ltd. | SK bioscience-Seoul National University Hospital Agree Clinical Trial Cooperation for COVID-19 Vaccine ‘NBP2001’ skbioscience.com ↗ |
| 2020-11-25 | SK Bioscience Co., Ltd. | SK bioscience’s COVID-19 Vaccine Candidate Enters Clinical Trial skbioscience.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NBP2001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04760743 ↗ |
| Modality | Vaccine | “a SK SARS-CoV-2 recombinant protein subunit vaccine (NBP2001) in healthy adults.” NCT04760743 ↗ |
| Route | Intramuscular | “Participants will receive intramuscular (IM) injections of NBP2001(RBD 30μg/dose) on Days 0 and 28.” NCT04760743 ↗ |